|
Verzögert
NSE India S.E.
10:47:33 16.09.2026
|
Perf. 5 T | Veränd. 1. Jan. | ||
| 1’359.70 INR | +0.64% |
|
-0.26% | -10.04% |
| 03.09. | Indiens Cipla und Chinas Qilu kooperieren für US-Start eines Keytruda-Biosimilars von Merck | RE |
| 25.08. | Ciplas Werk Pithampur in Indien erhält sieben Beobachtungen von der US-FDA | MT |
ETFs investiert in Cipla Limited
| Name | % 1. Jan. | Gewichtung | Volumen | |
|---|---|---|---|---|
| +11.39% | -.--% | 27 154 M€ | ||
| +13.14% | -.--% | 1 674 M€ | ||
| +6.32% | -.--% | 37 M€ | ||
| +10.12% | -.--% | 67 M€ | ||
| +19.11% | -.--% | 9 273 M€ | ||
| -12.05% | 2.13% | 118 M€ | ||
| -17.47% | 1.26% | 125 M€ | ||
| -14.25% | 1.12% | 48 M€ | ||
| -20.73% | 0.76% | 124 M€ | ||
| +22.44% | 0.75% | 122 M€ | ||
| -10.64% | 0.72% | 6 M€ | ||
| +46.49% | 0.72% | 18 M€ | ||
| -13.86% | 0.71% | 96 M€ | ||
| -13.43% | 0.69% | 5 254 M€ | ||
| -12.67% | 0.68% | 2 M€ | ||
| -21.53% | 0.66% | 108 M€ | ||
| -15.13% | 0.66% | 565 M€ | ||
| -11.95% | 0.55% | 6 661 M€ | ||
| +17.58% | 0.54% | 86 M€ | ||
| +16.12% | 0.53% | 3 601 M€ | ||
| +17.07% | 0.52% | 491 M€ | ||
| -11.26% | 0.51% | 99 M€ | ||
| +29.21% | 0.49% | 68 M€ | ||
| -9.15% | 0.47% | 2 189 M€ | ||
| -11.17% | 0.46% | 2 692 M€ | ||
| +28.10% | 0.45% | 148 M€ | ||
| -7.62% | 0.45% | 49 M€ | ||
| -10.63% | 0.4% | 2 054 M€ | ||
| -11.58% | 0.37% | 5 M€ | ||
| +21.15% | 0.28% | 60 M€ | ||
| +11.49% | 0.27% | 1 125 M€ | ||
| +18.90% | 0.26% | 180 M€ | ||
| +22.11% | 0.25% | 164 M€ | ||
| +6.97% | 0.25% | 1 545 M€ |
Beschäftigte
31’369
Sektor
Pharmazeutika
- Börse
- Aktien
- A0B5L5 Aktie
- ETFs Cipla Limited
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
















